CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 6, 2009--
Scientists from the Baylor
College of Medicine Human Genome Sequencing Center (HGSC) are
expanding their fleet of advanced genomic next-generation sequencing
technology from Applied Biosystems, part of Life Technologies
Corporation (NASDAQ:LIFE) to accelerate their studies of the genetic
underpinnings of cancer and other complex human diseases. Additional
SOLiD™ Systems will be integrated into the HGSC’s existing base of
genomics analysis technologies. With a total of 20 systems, HGSC
scientists will use these sequencing platforms to further conduct
comprehensive analyses of the genetic changes that characterize cancer,
autism and cardiovascular disease in humans.
The HGSC research developments coincide with the National Institutes of
Health Gene Sequencing Programs, including increased support for
determination of genetic changes in each of the three disease areas.
With the additional genomic analysis platforms and the increased
throughput available from each system, the HGSC expects to at least
triple its current sequence production.
The development of sophisticated genomic analysis sequencing
technologies has opened the door to a new era of life-science research,
enabling scientists to completely survey entire cancer genomes within
individuals. By creating a catalog of both single base changes, or SNPs,
and large segments of DNA rearrangements in genomes known as structural
variants, researchers hope to one day identify all sources of genetic
variation that contribute to cancer. This kind of portrait of the
genetic underpinnings of disease will help scientists to lay the
groundwork for the molecular events that occur in the generation of
individual cancers.
Richard
Gibbs, Ph.D., Director of Human Genome Sequencing Center at
Baylor College of Medicine
“In order to unravel the complexities of genomic disease, we need highly
accurate, cost-effective and ultra-high throughput sequencing
technology. Our experience with SOLiD demonstrates that the
industry-leading accuracy and throughput is ideal for the in-depth
analysis of complex genomes.”
Shaf Yousaf, President, Genomic Analysis at Life Technologies
“Baylor’s commitment to the SOLiD platform demonstrates that advanced
genomic analysis technology is an effective discovery and clinical
research tool that will ultimately advance personalized medicine.”
Supporting Resources
About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology
tools company dedicated to improving the human condition. Our systems,
consumables and services enable researchers to accelerate scientific
exploration, driving to discoveries and developments that make life even
better. Life Technologies customers do their work across the biological
spectrum, working to advance personalized medicine, regenerative
science, molecular diagnostics, agricultural and environmental research,
and 21st century forensics. Life Technologies had sales of more than $3
billion in 2008, employs approximately 9,500 people, has a presence in
more than 100 countries, and possesses a rapidly growing intellectual
property estate of approximately 3,600 patents and exclusive licenses.
Life Technologies was created by the combination of Invitrogen
Corporation and Applied Biosystems Inc. For more information on how we
are making a difference please visit our website: www.lifetechnologies.com.
Follow Life Technologies on Twitter @LIFECorporation
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies’ plans,
objectives, expectations and strategy for its business, contains
forward-looking statements that are subject to risks and uncertainties
that could cause actual results or events to differ materially from
those expressed or implied by such forward-looking statements. Any
statements that are not statements of historical fact are
forward-looking statements. When used, the words “believe,” “plan,”
“intend,” “anticipate,” “target,” “estimate,” “expect” and the like,
and/or future tense or conditional constructions (“will,” “may,”
“could,” “should,” etc.), or similar expressions, identify certain of
these forward-looking statements. Important factors which could cause
actual results to differ materially from those in the forward-looking
statements are detailed in filings made by Life Technologies with the
Securities and Exchange Commission. Life Technologies undertakes no
obligation to update or revise any such forward-looking statements to
reflect subsequent events or circumstances.
For Research Use Only. Not for use in diagnostic procedures.
Copyright 2009. Life Technologies Corporation. All rights reserved. AB
(Design), and Applied Biosystems are registered trademarks and SOLiD are
trademarks of Life Technologies or its subsidiaries in the United States
and/or certain other countries.
Source: Life Technologies
Life Technologies
Lauren Lum, 650-638-6916
lauren.lum@lifetech.com
